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ABSTRACT: Regulation of cellular death is central to nearly
all physiological routines and is dysregulated in virtually all
diseases. Cell death occurs by two major processes, necrosis
which culminates in a pervasive inflammatory response and
apoptosis which is largely immunologically inert. As necrosis
has long been considered an accidental, unregulated form of
cellular death that occurred in response to a harsh
environmental stimulus, it was largely ignored as a clinical target. However, recent elegant studies suggest that certain forms
of necrosis can be reprogrammed. However, scant little is known about the molecules and pathways that orchestrate calcium-
overload-induced necrosis, a main mediator of ischemia/reperfusion (IR)-induced cardiomyocyte cell death. To rectify this
critical gap in our knowledge, we performed a novel genome-wide siRNA screen to identify modulators of calcium-induced
necrosis in human muscle cells. Our screen identified multiple molecular circuitries that either enhance or inhibit this process,
including lysosomal calcium channel TPCN1, mitophagy mediatorTOMM7, Ran-binding protein RanBP9, Histone deacetylase
HDAC2, chemokine CCL11, and the Arp2/3 complex regulator glia maturation factor-γ (GMFG). Notably, a number of
druggable enzymes were identified, including the proteasome β5 subunit (encoded by PSMB5 gene), which controls the
proteasomal chymotrypsin-like peptidase activity. Such findings open up the possibility for the discovery of pharmacological
interventions that could provide therapeutic benefits to patients affected by myriad disorders characterized by excessive (or too
little) necrotic cell loss, including but not limited to IR injury in the heart and kidney, chronic neurodegenerative disorders,
muscular dystrophies, sepsis, and cancers.
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Heart disease is the leading cause of morbidity andmortality in the developed world. Nearly 1.5 million
people experience an acute myocardial infarction (MI) each
year in the United States alone, and up to 1/3 of survivors
continue to suffer from ischemic cardiomyopathy. Cardiac
ischemia is also pervasive in adult patients particularly women
and/or those with underlying congenital heart diseases that
afflict up to 1% of live births. Cardiac ischemia leads to oxygen
and nutrient deprivation and stimulates both apoptotic and
necrotic cardiomyocyte death (which occur at roughly equal
levels following MI). Because cardiomyocytes have very
limited regenerative potential, ischemic cell death inevitably
reduces heart function and leads to heart failure. The fact that
the pathological progression of disease is markedly accelerated
by the inflammatory responses prompted by myocyte necrosis
highlights the importance of discovering the underlying
mechanisms.1,2
Cell death occurs by two major processes, apoptosis and
necrosis. Apoptosis is a highly regulated, programmed process
that is controlled by proteolytic caspases, is dependent on
ATP, and is largely immunologically inert. The absence of an
inflammatory response is due to the piecemeal fashion by
which cell contents are cleared wherein membrane blebbing
leads to the progressive release and clearing of encapsulated
apoptotic bodies by macrophages while the plasma membrane
remains intact. Conversely, necrotic cell death involves loss of
plasma membrane integrity, osmotic-pressure-induced cell and
organelle swelling, ATP depletion, and ultimately plasma
membrane rupture. Necrotic release of cellular contents
(including factors that contain so-called damage-associated
molecular patterns) culminates in a pervasive inflammatory
response. As necrosis has long been considered an accidental,
unregulated form of cellular death that occurred in response to
a harsh environmental stimulus (i.e., a dramatic change in
osmotic pressure, pH, or temperature), it was largely ignored
as a clinical target. However, recent elegant studies have
uncovered signaling pathways that govern certain forms of
necrosis.3 Such findings open up the possibility for the
discovery of future pharmacological interventions that could
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provide therapeutic benefits to patients affected by myriad
disorders characterized by excessive (or too little) necrotic cell
loss, including but not limited to IR injury in the heart.
The most well-characterized necrotic pathway described to
date is a process coined “necroptosis” which is induced by the
tumor necrosis factor (TNF) family of cytokines. A series of
elegant studies revealed that TNFα treatment induces necrosis
by promoting assembly of a multiprotein complex containing
receptor-interacting protein kinase 1 (RIPK1), RIPK3, and
mixed lineage kinase domain-like (MLKL), while TNFα
promotes apoptosis by bridging RIPK1 to other intermedi-
ates.4−7 During necrosis, phosphorylation of MLKL by RIPK3
induces translocation of MLKL to the plasma membrane,
wherein it forms a plasma membrane pore and results in the
influx of calcium and sodium ions. This osmotic instability
ultimately leads to plasma membrane rupture by incompletely
understood processes that are largely independent of
mitochondrial dysfunction. Importantly, pharmacological
intervention upstream of MLKL translocation (and calcium
influx) attenuated TNF-induced necrotic death. Such results
provide important proof of concept that enzymatic regulators
of necroptosis could be useful therapeutic targets for
inflammatory-mediated cell death.
However, the main triggers of ischemia-induced necrotic cell
death are oxidative stress and calcium overload, and these
insults induce a distinct form of regulated necrosis that is
associated with cyclophilin D dependent mitochondrial
permeability transition (MPT).8,9 While MPT-associated
necrosis has been linked to myriad cardiovascular, muscu-
loskeletal, and neural diseases8−12 and studies suggest that
molecules that function to regulate sarcolemmal-10 or
mitochondrial-stability13,14 are critical regulators of IR-
mediated necrosis, scant little is known about the specific
molecules and pathways that orchestrate these processes. To
rectify this critical gap in our knowledge, we recently
performed a novel genome-wide siRNA screen to identify
modulators of calcium-induced necrosis in human muscle cells.
Our screen revealed several critical and novel cellular processes
and signaling pathways involved in protecting cells from
necrosis. In addition, we also identified the ubiquitin-
proteasome pathway as essential executors of calcium-over-
load-induced necrosis in human cardiomyocytes and provided
support for the possibility that targeting the proteasome might
provide a therapeutic avenue for limiting cardiac injury.
Overall, this knowledge provides a rich resource to better
understand necrosis and could facilitate the development of
novel therapies for heart disease and other degenerative
disorders.
■ METHODS
Cell Culture. Human bronchial smooth muscle cells
(HuBrSMCs, CC-2576, Lonza) were maintained in SmGM-2
Smooth Muscle Growth Medium-2 (CC-3182, Lonza).
Transfection with siRNAs was performed with DharmaFECT
1 transfection reagent in SmGM-2 media without gentamycin
to reduce cytotoxicity as per manufacturer’s instructions.
Human adult cardiomyocytes (HCMs, 36044−15, Celprogen)
were maintained in Human Cardiomyocyte Complete Media
with Serum (M36044−15S, Celprogen). Transfection with
siRNAs was performed with Lipofectamine RNAiMAX
Transfection Reagent in Human Cardiomyocyte Complete
Media. Neonatal rat cardiomyocytes (NRCMs) were isolated
from 2 to 4 day old Wistar rats using the Neonatal
Cardiomyocyte Isolation System (Worthington Biochemical
Corporation, NJ) and seeded in Media 199 supplemented with
15% fetal bovine serum (FBS) and 1% penicillin/streptomycin
as described previously.15 At 24 h, the culture media was
switched to serum-free Media 199 followed by siRNA
transfection using HiPerfect transfection reagent (Qiagen) or
treatment with indicated chemicals. The siRNA sequences
used were as follows: siPSMB5: CAUGGUGUAUCAGUA-
CAAA[dT][dT]; siPSMA6: UACAAAUAUGGCUAUGAGA-
[dT][dT]; siControl: UAAGGCUAUGAAGAGAUAC[dT]-
[dT]. The following drug concentrations were used:
ionomycin (0.5 μM), bortezomib (1 μM).
siRNA Screens and Statistical Analysis. All screens were
performed with automated liquid handling and plate
preparation using the Beckman Coulter Biomek FXP assay
workstation and the BioTek MicroFlo Select reagent
dispensers. Cell viability data were recorded with BMG
Labtech Pherastar FS high-throughput screening plate reader.
The primary siRNA screen was performed with the
Dharmacon human genomic siRNA library (72 700 siRNAs
targeting 18 175 genes). Human bronchial smooth cells
(HuBrSMCs, passage 10, 700 cells/well) were transfected
with pooled siRNAs (25 nM) using DharmaFECT 1
transfection reagent (0.05 μL/well, Dharmacon) in 384-well
clear-bottomed white plates (Greiner). Cells were incubated at
37 °C/5% CO2 for 96 h and then treated with ionomycin (5
μM, Cayman Chemical) for 4 h to induce necrosis. Cell
viability, which has been effectively used as a measure of
necrosis in a previous siRNA screen,16 was determined by
measuring intracellular ATP levels using CellTiter-Glo
luminescent assay reagent (Promega) according to the
manufacturer’s protocol. Nontargeting siRNAs and human
UBB siRNAs (Dharmacon) which served as negative and
positive controls for siRNA transfection, respectively, were
present in every plate. The UBB gene encodes ubiquitin, which
targets cellular proteins for degradation by the 26S
proteasome. Cells lacking ubiquitin are universally lethal;
thus, UBB siRNA is routinely used in RNAi screens to monitor
transfection efficiency. Treatment with ionomycin or vehicle
control were each performed in triplicate.
The secondary screen was conducted against the top 200
ranked genes (100 positive and 100 negative regulator of
necrosis) using 4 individual siRNAs for each gene. A hit was
verified if at least 2 out of 4 siRNAs targeting a single gene
altered cell viability by ≥30% and had a p-value < 0.05 versus
nontargeting-siRNA-transfected wells.
For both the primary and secondary screens, count data
corresponding to siRNA screen targets were normalized to
counts from nontargeted control wells by plate and row of the
plate. Normalized estimates were log-transformed and tested
for differential abundance using the Significance Analysis for
Microarray17 algorithm implemented in R package samr. The
SAM two-class unpaired test was performed, and screen
candidates were evaluated based on the SAM empirical q-value
and the fold change of count between experimental conditions.
Screen candidates were excluded if counts in the experimental
control samples were less than the 99th percentile of counts
from UBB control wells.
Hits from the secondary screen were selected for a tertiary
siRNA screen in human cardiomyocytes (Celprogen) accord-
ing to the following criteria: (1) At least 2 of the 4 individual
siRNAs per gene agreed in effect directionality. (2) Positive
regulators of necrosis had a log2 (fold change) greater than 1.2.
(3) Negative regulators of necrosis had a log2 (fold change)
less than −1.5. Therefore, the tertiary screen was performed
against 73 genes (23 positive and 50 negative regulators of
necrosis) using a pool of the top 2 siRNAs per gene. Human
cardiomyocytes (80% confluent) were transfected in 96-well
white-walled clear-bottomed plates with 25 nM siRNA. Cells
were incubated at 37 °C/5% CO2 for 72 h and then treated
with ionomycin (15 μM, Cayman Chemical) for 4 h to induce
necrosis. Cell viability was measured via CellTiter-Glo, as in
the previous screens. Additionally, supernatant from each well
was removed to separate 96-well plates for use with
Cytotoxicity Detection Kit (LDH) (11644793001, Roche)
Figure 1. RNAi screen for regulators of necrosis. (A) Schematic diagram of the RNAi screen. (B) Scatter plot of log-transformed, nontargeting
siRNA-normalized signed fold change of ATP levels in pooled siRNA-transfected cells. Data points are ordered from most negative (inhibitors) to
most positive (enhancers). Dashed red or green lines are screen-specific cutoffs for inhibitors or enhancers, respectively. Dashed grey line indicates
nontargeting control siRNAs. (C) Volcano plot of the t-test q-value (negative log10) against the signed fold change (log2) from the primary screen.
The horizontal blue line indicates the statistical significance level (q = 0.05), and the vertical blue lines represent a signed fold change of ±2.
Necrosis inhibitors (red dots, 1084) are defined as genes with a signed fold change less than −2 and q < 0.05; necrosis enhancers (green dots, 743)
are defined as genes with a signed fold change greater than 2 and q < 0.05. (D) Pie chart showing the percentages of necrosis inhibitors and
enhancers in the human genome based on data from the primary screen.
according to the manufacturer’s instructions. As before,
nontargeting siRNAs and human UBB siRNAs (Dharmacon)
served as negative and positive controls. For each run,
CellTiter-Glo and LDH luminescence values were blanked
against media alone. Sample means and standard errors were
calculated; target means were normalized to nontargeting
siRNA means. For each gene target, mean normalized values
were calculated across all runs, and fold changes were
calculated for ionomycin treatment versus vehicle only
treatment. Error was propagated through all calculations
according to appropriate formulas; one-sample two-tailed t-
tests were performed with a null hypotheses of fold change
equals 1. Significance was defined as p < 0.05, and whiskers
were plotted for means ± standard errors.
Western Blotting. Cell lysates were loaded on to an SDS-
PAGE gel for electrophoresis. Proteins were then transferred
onto a polyvinylidene fluoride (PVDF) membrane and
incubated with the following antibodies: rabbit anti-PSMA6
(#2459, Cell Signaling, 1:1000), rabbit anti-PSMB5 #12919,
Cell Signaling, 1:1000), rabbit anti-GAPDH (sc-25778, Santa
Cruz, 1:1000), and mouse anti-α-tubulin (T6074, Sigma,
1:1000).
Figure 2. Enrichment of functional groups, biological processes and pathways in ionomycin-induced necrosis. (A) Candidate genes from the
primary screen were grouped by molecular function using the PANTHER classification system. Top molecular functions related with necrosis were
catalytic activity and binding. (B) Detailed protein categorization of the catalytic activity group in panel (A). Hydrolase and transferase activities
were the primary catalytic activities involved in necrosis. (C) Candidate genes from the primary screen were grouped by biological process using
the PANTHER classification system. More than half of all hits were associated with cellular and metabolic processes. (D) Detailed protein
categorization of the cellular process group in panel (C). Cell communication and cell cycle were the predominant cellular processes identified. (E)
Highly scored pathways in ionomycin-induced necrosis based on PANTHER pathway analysis.
■ RESULTS AND DISCUSSION
Genome-Wide siRNA Screen Identified Novel Genes
Modulating Ionomycin-Induced Necrosis. Necrosis is
now considered a controllable cell death routine, and studies
suggest that several distinct, but likely interconnected, signal
transduction pathways are in place to trigger necrotic death.
However, details are largely unknown regarding the precise
pathways involved, particularly those downstream of calcium
overload which is the major inducer of ischemia-induced cell
death. The overarching goal of this study was to identify novel
mediators of cardiomyocyte necrosis to aid in the future
development of therapeutic strategies to mitigate cardiac
injury. To this end, we developed an automated assay to
perform a rigorous, unbiased genome-wide screen to identify
modulators of necrosis induced by the effective Ca2+
ionophore, ionomycin, which acts in a fashion similar to that
of MLKL to promote Ca2+ influx and is a well-established
inducer of necrosis in a number of cell types.8,9
We utilized human smooth muscle cells as a surrogate
muscle cell line for the primary and secondary screens and then
validated these genes in a tertiary assay using human
cardiomyocytes (Figure 1A). Smooth muscle cells were chosen
due their relative ease of use and inexpensive application as
cardiomyocytes can only be passaged a limited number of
times and require specialized extracellular-matrix-coated plates.
Moreover, smooth muscle cells share many features with
cardiomyocytes including (but not limited to) (1) sarcoplas-
mic reticulum controlled Ca2+-dependent excitation-relaxation
coupling, (2) a high mitochondrial density relative to
Figure 3. Protein interaction networks in ionomycin-induced necrosis. Potential protein−protein interactions between top candidates from the
secondary screen were analyzed using the STRING program. (A) Necrosis enhancers; (B) necrosis inhibitors. Specific groups of genes discussed in
the text were indicated by arrows. The different colors for proteins were used only as a visual aid.
nonmuscle cells, (3) a similar oxidative phosphorylation
capacity of individual mitochondria, and (4) the need for
basal mitochondrial activity to meet short-term energy
demands.18,19
For the primary screen, we performed a two-condition
triplicate analysis screen with the Dharmacon human genomic
siRNA library that contains 72 700 siRNAs targeting 18 175
genes. In brief, human smooth cells (Celprogen, passage 10,
700 cells/well) were transfected with pooled gene-specific
siRNAs (25 nM, 4 siRNAs/gene) and either negative control
nontargeting siRNAs or siRNAs for human UBB (a gene
essential for cell viability) which served as a positive control for
transfection. The siRNA screen repeatedly showed an assay
window of >80% by comparing the cell viability in UBB and
nontargeting siRNA transfected controls that were transfected
in alternating rows of each plate (Figure S1A). At 96 h
following transfection, cells were treated with vehicle or
ionomycin (IC50 = 5 μM, Cayman Chemical; Figure S1B) for
4 h to induce necrosis and cells were subjected to a Cell Titer
Glo assay to quantify cellular ATP.
To determine essential cellular signaling networks that were
specific to ionomycin-induced death, we subjected this data set
to SAMq and signed-fold change- statistical analyses that rank
genes based on their effect size with ionomycin treatment
relative to their effect without treatment. Using this approach
we effectively filtered out genes that influenced basal cell
viability as such genes would not likely be good therapeutic
targets. This analysis revealed 1084 genes that significantly (p
< 0.05) enhanced ionomycin-induced necrosis with a signed
fold change > 2 and 743 hits that inhibited necrosis with a
signed fold change < 2 when compared with nontargeting
siRNA-transfected controls (Figure 1B,C). Importantly, known
necrosis regulators were identified along with numerous other
novel genes that were even more efficacious necrosis enhancers
or inhibitors respectively (Excel File S1). As shown in the
Volcano plot in Figure 1C, 168 genes enhanced necrosis with a
signed fold change > 3 and 120 genes inhibited necrosis with a
signed fold change < 3 (q < 0.05). Overall, the primary screen
indicated that 6.0% of genes in the human genome have the
potential to enhance necrosis and that 4.1% of human genes
encode proteins that function as endogenous inhibitors of
necrosis (Figure 1D).
Subjection of this very exciting initial data set to pathway
enrichment analysis using Ingenuity Pathway Analysis (IPA,
Qiagen, www.ingenuity.com), the STRING database (http://
string-db.org; KEGG pathways), and PANTHER revealed
some expected and many unexpected findings (Figures 2 and
3; Tables 1 and 2). As expected, the highest number of genes
segregated with known Cell Death and Survival pathways and
the highest functional subcategory was cardiovascular toxicity
with the top canonical pathway being protein ubiquitination.
Hypoxia signaling in the cardiovascular system was also a top
pathway, which suggests that functional overlap exists between
ionomycin-induced necrosis and cell death induced by
ischemic heart disease. Several genes involved in integrin
signaling were also identified, which is consistent with reports
that loss of the cysteine-protease cathepsin S or overexpression
of thrombospondin-4 proved effective in blunting skeletal
muscle necrosis in dystrophic mice by mechanisms that
involved increased dependence of plasma membrane stabiliza-
tion on integrin−extracellular-matrix interaction.20
However, many novel genes were identified, and a
breakdown of the catalytic activities involved in necrotic
execution revealed that a remarkably diverse group of enzymes
are involved including hydrolases, transferases, oxoreductases,
ligases, lyases, and helicases (Figure 2). These findings indicate
that a combinatorial inhibitor approach will likely be required
to mitigate necrosis. Some surprises were also found when
exploring protective genes, in that this list included an over-
representation of genes involved in cell−cell communication
(Figure S2).
We next performed a secondary validation screen in which
we utilized four individual siRNAs to target 100 necrosis
enhancers (signed fold change >2) and 100 necrosis inhibitors
(signed fold change < 2). Top-ranking necrosis-regulating
genes from the secondary screen were identified by selecting
Table 1. Functional Classification of Candidate Genes and
Major Signaling Pathways Involved in Ionomycin-Induced




Molecular and Cellular Functions
cell death and survival 4.81 × 10−09−1.12 × 10−02 405
gene expression 6.50 × 10−09−1.04 × 10−04 251
cellular growth and
proliferation
8.41 × 10−08−1.16 × 10−02 383
post-translational modification 2.54 × 10−07−8.83 × 10−03 82
protein degradation 2.54 × 10−07−5.31 × 10−06 65
Cardiovascular Toxicity
cardiac infarction 3.54 × 10−04−3.84 × 10−01 26
heart failure 3.39 × 10−03−5.46 × 10−01 26
cardiac pulmonary embolism 4.52 × 10−02−9.66 × 10−02 4
cardiac congestive cardiac
failure
5.70 × 10−02−5.70 × 10−02 10
cardiac arrhythmia 9.15 × 10−02−5.89 × 10−01 19
Top Canonical Pathways
name p-value ratio
protein ubiquitination pathway 8.09 × 10−16 68/254
(0.268)
glucocorticoid receptor signaling 7.42 × 10−06 47/258
(0.182)
hypoxia signaling in the cardiovascular
system
4.91 × 10−05 17/63 (0.27)
PPARa/RXRa activation 1.41 × 10−04 31/165
(0.188)
cAMP-mediated signaling 1.01 × 10−03 35/216
(0.162)







ubiquitin mediated proteolysis 40 2.43 × 10−10
proteasome 19 6.78 × 10−08
neuroactive ligand−receptor
interaction
50 1.11 × 10−05
Epstein−Barr virus infection 37 9.85 × 10−05
viral carcinogenesis 33 0.00136
metabolic pathways 137 0.00239
NF-κB signaling pathway 19 0.00523
HTLV-I infection 39 0.00594
pathways in cancer 45 0.017
chronic myeloid leukemia 15 0.017
cyanoamino acid metabolism 4 0.0357
inositol phosphate metabolism 13 0.0357
type I diabetes mellitus 10 0.0357
those in which at least 2 out of the 4 siRNAs significantly
altered cell survival (q < 0.05 versus nontargeting siRNA).
These criteria identified 23 necrosis enhancers and 50 necrosis
inhibitors as validated targets (Excel File S2). To further
analyze potential physical interactions and functional associa-
tions between the proteins encoded by these genes, we again
ran these hits through the STRING database (http://string-db.
org). As shown in Figure 3, the proteasome and cullin3
remained among the major protein complexes required for
ionomycin-induced necrosis. Integrin family members integrin
β1 and β3 appeared to play counteractive roles in necrosis,
with β1 being a necrosis enhancer and β3 as well as the
associated Rho-associated protein kinase 1 (ROCK1) being
antinecrotic. Interestingly, chemokines CXCL12 (C−X−C
motif chemokine ligand 12) and CCL11 (C−C motif
chemokine 11) were also identified as necrosis inhibitors,
suggesting that inhibition of necrosis may represent a novel
mechanism underlying CXCL12/CXCR4-dependent cardio-
protection.21 Finally, major protein kinase subunits PIK3C2G
(phosphoinositide 3-kinase (PI3K) family kinase catalytic
subunit), PRKCE (protein kinase C epsilon (PKCε)), and
PRKAR1A (protein kinase A type 1a regulatory subunit) are
also among the highly scored hits, indicating that PI3K, PKC,
and PKA pathways may play a role in ionomycin-induced
necrosis.
Screen for Necrosis Regulators in Human Cardio-
myocytes. To aid in the identification of key regulators of
cardiomyocyte necrosis, we performed a tertiary screen in
cultured human cardiomyocytes (Cellprogen). Moreover,
because permeabilization of the plasma membrane and release
of intracellular enzymes such as lactate dehydrogenase (LDH)
is a key signature for necrotic cells (but not apoptotic cells), we
modified this tertiary screen to assess both intracellular ATP
and extracellular LDH levels. We obtained a reliable z-score of
0.7 with an ionomycin IC50 of 15.5 μM using Cell Titer Glo as
a readout for ATP levels in these cells (data not shown). The
higher resistance to ionomycin likely results from the
remarkable ability of cardiomyocytes to maintain calcium
homeostasis by sequestration into intracellular compartments
(including t-tubules which are not present in smooth muscle
cells) and/or by active transport across the plasma membrane.
Importantly, 40 out of 50 of the protective genes identified in
our secondary screen in human bronchial smooth muscle cells
also protected human cardiomyocytes from ionomycin-
mediated ATP depletion, while 7 of the identified 23 necrosis
enhancers exacerbated ionomycin-mediated ATP depletion in
cardiomyocytes (Excel File S3). With respect to LDH release,
13 of the 23 necrosis enhancers and 30 of the 50 protective
genes from secondary screen had a reciprocal effect on LDH
release in cardiomyocytes (Excel File S3), though only 7
inhibitors and 3 enhancers reached statistical significance of p
< 0.05 in this assay (Figure 4). While several modifiers of
cardiac necrosis were identified using this work flow, known
differences between cardiomyocytes and smooth muscle cells
in mitochondrial abundance, proton leakage, and ROS
production (among others) may have limited our ability to
identify some relevant targets for cardiac necrosis in the
present study. Indeed, while our systematic approach to
perform the primary and secondary screens in smooth muscle
cells followed by a tertiary screen in cardiomyocytes was
designed to rule out putative false positives, false negatives are
formally possible.
One of the protective genes we identified in our tertiary
screen as assessed by LDH release, the lysosomal calcium
channel TPCN1, is a previously confirmed regulator of
cardiomyocyte autophagy and cell death. Autophagy is an
evolutionarily conserved intracellular degradation/recycling
system that is fundamental for cellular homeostasis and
metabolism22−24 and generally refers to the process by which
organelles or long-lived proteins are engulfed by a double-
membraned autophagosome structure, which then fuses with
lysosomes for degradation. Autophagy is enhanced following
cardiac IR and inhibition of autophagy with bafilomycin A,
which blocks lysosomal-mediated autophagosome degradation,
worsens IR injury, and promotes the accumulation of damaged
mitochondria under these conditions.31 TPCN1 functions to
aid in autophagosome−lysosome fusion, and prior studies
revealed that silencing of TPCN1 had no impact on
cardiomyocyte viability under control culture conditions, but
rather it significantly decreased the viability of cardiomyocytes
exposed to ischemia or starvation.25 These studies are
consistent with our findings and serve as validation of our
approach to identify selective mediators of calcium-induced
cardiomyocyte necrosis.
Another necrotic inhibitor we identified in our tertiary
screen, TOMM7 (a component of the protein translocase of
the outer mitochondrial membrane (TOM) complex),
regulates a selective form of autophagy that removes damaged
mitochondria referred to hereafter as mitophagy. Since
mitochondria produce reactive oxygen species (ROS) as a
byproduct of electron transport, even slight dysfunction can
disrupt cellular redox balance leading to adverse lipid and
protein modifications, the generation of toxic lipid inter-
mediates, and mitochondrial DNA damage, all of which further
perpetuate mitochondrial dysfunction and cell death.26,27
Although several mitochondrial quality control mechanisms
have been described including mitochondrial fission and
fusion, selective degradation of dysfunctional mitochondrial
proteins, and mitochondrial biogenesis,28 mitophagy is thought
to be the most important in nondividing cells such as
cardiomyocytes and neurons.29,30 Several major cardiomyocyte
mitophagy pathways have recently been described that involve
accumulation of the serine/threonine kinase PINK1 on the
Figure 4. Tertiary RNAi screen data for regulators of cardiomyocyte
necrosis as assessed by LDH. Bar graph of LDH log2 (fold change) for
significant (p < 0.05) targets which recapitulated the secondary screen
results.
outer membrane of damaged mitochondria, an event that
promotes binding of the cytosolic E3 ubiquitin ligase, Parkin,
followed by the subsequent ubiquitin-dependent recruitment
of mitochondria into double-membraned autophago-
somes.31−36 Interestingly, TOMM7 was originally identified
in a screen for regulators of mitophagy and was subsequently
shown to play a major role in the recruitment of Parkin to
damaged mitochondria in neurons by promoting PINK1
stabilization.37 While a functional role for TOMM7 in
cardiomyocytes has not yet been reported, it is clear that
Parkin has important cardioprotective functions. For example,
depletion of Parkin or dynamin-related protein 1 (Drp1), a
protein that inhibits mitochondrial fission and mitophagy, led
to exacerbated injury following IR,38,39 while the protective
effects provided by ischemic preconditioning were abolished in
Parkin KO mice.40 Thus, future studies on TOMM7 functions
in the context of cardiac IR are warranted.
Additional genes that we identified as putative cardiopro-
tective agents are consistent with their known functions. For
example, we found that silencing of the Ran-binding protein,
RanBP9, induced ionomycin-mediated cardiomyocyte ne-
crosis. RanBP9 is highly expressed in the heart, but it has
been primarily studied in cancer cells in which it has been
shown to promote apoptosis.41 Mechanistically, RanBP9
downregulation promotes the expression of antiapoptotic
Bcl-2 family members Bcl-2 and Bcl-XL and, as a consequence,
genotoxic-dependent recruitment of the pro-apoptotic family
member Bax (which initiates activation of apoptosis by
inducing mitochondrial permeabilization and cytochrome c
release) is blunted in RanBP9-deficient cells.41 Since necrosis is
often induced under conditions where apoptosis is blocked,42
these findings are consistent with our studies. However, they
also indicate that RanBP9 targeting would not likely be
therapeutically efficacious in the context of cardiac IR.
Similarly, we found that HDAC2 depletion protected cells
from ionomycin-mediated necrosis which is consistent with
previous findings that HDAC2 is necessary for normal cardiac
development.43 However, several groups have demonstrated
that pan HDAC inhibitors can reduce infarct size and attenuate
heart failure in preclinical animal models of MI and IR.44
Taken together, our data support the idea that isoform-
selective HDAC inhibitors (which do not target HDAC2) may
be more beneficial for the treatment of cardiovascular disease.
Two of the three top hits in our screen for cardioprotective
agents are inflammatory mediators. CCL11 is a well-known
cytokine, and PTPN6 has been shown to work in concert with
the necrosis regulator RIPK1 to drive an NF-κB-mediated
inflammatory signaling cascade in hematopoietic cells.45 While
inflammation certainly plays a critical role in tissue damage
following cardiac IR, the finding that these molecules provided
protection to acute ionomycin-mediated cardiomyocyte death
was somewhat surprising. However, it is known that mild
activation of the innate immune axis can be protective against
IR damage.46 Thus, it is formally possible that in our model,
silencing of these genes attenuated a basal level of
“preconditioning” prior to ionomycin treatment. It is also
clear that cardiomyocytes secrete various cytokines which
govern autocrine, paracrine, and endocrine functions including
contractility, angiogenesis, local and systemic inflammation,
and organismal metabolism.47−49 Of particular relevance to our
findings, cardiomyocyte-restricted depletion of CXCR4 (the
alpha chemokine receptor for the CCL11-related family
member, CXCL12) exacerbated isoproterenol mediated
cardiac injury in vivo, indicating a myocyte-autonomous
protective role for this cytokine receptor.21 When taken
together, these studies reveal the exciting possibility that
CCL11 secretion may promote the establishment of an
antinecrotic state among neighboring cardiomyocytes.
Finally, our top cardioprotective candidate, GMFG, is a
novel antinecrotic target. This gene is a member of the ADF/
cofilin family which binds to Arp2/3 and serves to
depolymerize actin. It has long been known that localized
actin polymerization is necessary for mitochondrial fission and
for mitochondrial movements.50 Interestingly, dephosphory-
lated cofilin is known to be targeted to mitochondria where it
regulates DRP-1 mediated mitochondrial fission and mitoph-
agy.51,52 While a direct role for GMFG in this process has not
yet been shown, very recent findings that GMFG associates
with the mitochondrial membrane ATPase ATAD3A,53 which
itself functions to mediate DRP-1-dependent mitochondrial
fission,54 indicate that GMFG may also play a critical role in
mitochondrial quality control. Our findings that GMFG
depletion reciprocally regulated ATP and LDH levels in
ionomycin-stimulated cardiomyocytes supports a role for this
protein in regulating MTP-dependent necrosis (Figure 4 and
Excel File S3).
Targeting the Proteasome for Cardioprotection.
Because we were particularly interested in prioritizing
druggable targets that could most likely impact human health,
we chose to further validate the effect of targeting genes which
served as executors of ionomycin-induced necrosis. To this
end, we focused on the proteasome as we identified several
subunits including PSMA1, 6, 7, and PSMB5 as enhancers of
ionomycin-induced necrosis. To further validate these genes as
targets for cardioprotection, we utilized isolated neonatal rat
cardiomyocytes (NRVCMs) because they exhibit many of the
characteristic features of their adult counterparts, and unlike
the human cardiomyocyte cell line used for the tertiary screen,
these cells do not divide in culture.15,55 We first focused on
PSMB5 which encodes the proteasome β5 subunit and
contains the chymotrypsin-like active site.56 As shown in
Figure 5A, transfection with siRNA utilized for our tertiary
screen resulted in >50% depletion of PSMB5 protein in
NRVCMs. Importantly, PSMB5-depleted NRVCMs exhibited
significantly increased cell viability (as measured by the MTT)
and reduced LDH release following ionomycin treatment when
compared to cells treated with control siRNA (Figure 5B).
Similar results were obtained when the PSMA6 subunit was
depleted in these cells (Figure S3).
To further corroborate our findings, we tested the possibility
that bortezomib (BTZ), a reversible inhibitor that binds the
proteasome β5 subunit, would limit ionomycin-mediated
necrosis. Indeed, as shown in Figure 5C, BTZ significantly
attenuated LDH release and enhanced cell viability in
ionomycin-treated NRVCMs. Similarly, previous studies
showed that TNF-induced necroptosis was attenuated by
carfilzomib, an irreversible proteasomal inhibitor that represses
the chymotrypsin-like activity.57 Thus, while our study focused
exclusively on calcium-mediated necrosis, the findings may be
more broadly applicable. Indeed, previous studies in HeLa cells
found that necrosis induced by calcium ionophore TNFα and
ROS utilize overlapping mechanisms for necrosis execution.58
Importantly, previous studies indicated that the proteasome
inhibitor PS-51959,60 attenuated IR injury in preclinical mouse
models. Likewise, proteasome inhibition with BTZ also
protected against IR injury in skeletal muscle,61 peripheral
nerve,62 retina,63 and steatotic liver,64 and proteasome
inhibition with epoxomicin was associated with cardioprotec-
tion in hypertrophic cardiomyopathy.65 Collectively, these
findings suggest that proteasome inhibition may provide
protection from IR, at least in part, through repression of
necrosis.
Cardiotoxicities are particularly prevalent in patients under-
going systemic therapy for malignancies, and in certain cases,
this outcome results from drug-induced cardiotoxicity,
particularly in patients who receive anthracycline-based
treatments. Bortezomib is currently approved in the treatment
of multiple myeloma and mantle cell lymphoma,56 and
somewhat surprisingly, some case reports have described
cardiac failure and other cardiotoxicities in treated pa-
tients.66,67 However, a recent meta-analysis of data from
5718 patients failed to show significant cardiotoxicity with
BTZ treatment.67 Thus, taken together with our findings and
the preclinical studies described above, it is likely that the small
subset of affected patients identified in these case studies may
have suffered from pre-existing cardiovascular disease and/or
elevated cardiovascular risk factors. Nonetheless, further
studies are necessary to more fully understand the potential
therapeutic value of bortezomib and related proteasomal
inhibitors as cardioprotective agents.
■ CONCLUSIONS
We designed and applied an innovative automated, high-
throughput, whole-genome siRNA discovery-based approach
to identify human genes that specifically enhance or inhibit
calcium overload-induced cardiomyocyte necrosis, a poorly
understood area in which there is a pressing need to develop
greater insight. Importantly, it is becoming increasingly clear
that drug discovery and development are hampered by high
attrition rates that are largely attributed to over reliance on
model systems that do not adequately reflect processes in
human organs. By starting with an unbiased screen in human
muscle, then moving in the future to animal models for in vivo
validation, we feel that our approach has a high likelihood of
identifying clinically relevant targets for MI. It is noteworthy
that human bronchial smooth muscle cells (HuBrSMCs) lack
many characteristics of adult cardiomyocytes, such as the t-
tubule system, mitochondrial abundance, terminal differ-
entiation state, and so on. Therefore, it is possible that certain
genes involved in necrosis may have not been picked in our
screen. Nonetheless, this data set could prove useful for future
risk ratio predictions as several genes we identified are current
clinical targets for the treatment of non-CVD related
pathologies and other disease-related polymorphisms. Finally,
as many of these genes will likely have conserved functions in
additional cell types, the future use of this knowledge could
prove useful to attenuate excessive cell loss that accompanies
muscular dystrophies or IR-mediated injury of the kidney,
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